DOI: https://doi.org/10.22141/2224-0713.2.96.2018.130483
Cholinesterase inhibitors in the therapy of dementia: clinical and pharmacological aspects
Abstract
Keywords
Full Text:
PDF (Русский)References
Бачинская Н.Ю. Лечение болезни Альцгеймера: современные возможности и перспективы // НейроNews. — 2013. — № 2(1). — С. 10-17.
Безруков В.В., Полюхов А.М., Бачинская Н.Ю. и др. Распространенность деменции среди жителей г. Киева старшего возраста, скрининговое исследование 2001–2002 гг. // Таврич. журн. психиат. — 2004. — Т. 8, № 1. — С. 47-51.
Бурчинський С.Г. Вік-залежна патологія центральної нервової системи: від фармакології до фармакотерапії // Рац. фармакотер. — 2010. — № 2. — С. 30-33.
Бурчинский С.Г. Ингибиторы холинэстеразы в фармакотерапии деменций // Рац. фармакотер. — 2011. — № 1. — С. 57-59.
Гаврилова С.И. Ривастигмин в терапии болезни Альцгеймера // Психиат. и психофармакотер. — 2011. — № 2. —
С. 14-19.
Дамулин И.В. Смешанная деменция // Когнітивні порушення старінні: Мат-ли наук.-практ. конф. Київ, 30–31 січня 2007 р. — К., 2007. — С. 24.
Дамулин И.В. Использование ривастигмина при деменциях: от симптоматического эффекта к нейропротекции // Журн. неврол. и психиат. — 2010. — Т. 110, № 9. — С. 76-82.
Дробижев М.Ю., Федотова А.М., Кикша С.В. и др. Фармакотерапия и деменция // Журн. неврол. и психиат. — 2016. — Т. 116, № 8. — С. 110-116.
Колыхалов И.В., Рассадина Г.А., Гаврилова С.И. и др. Холинергическая терапия болезни Альцгеймера и ее влияние на здоровье и качество жизни ухаживающих за больными лиц // Журн. неврол. и психиат. — 2010. — Т. 110, № 5. — С. 33-38.
Левада О.А. Болезнь Альцгеймера: от патогенеза до современных стратегий модифицирующей терапии // НейроNews. — 2006. — № 1. — С. 18-22.
Левин О.С. Диагностика и лечение деменции с тельцами Леви // Consilium Medicum. — 2006. — Т. 8, № 8. — С. 34-39.
Левин О.С., Батукаева А.А., Смоленцева И.Г. Диагностика и лечение деменции при болезни Паркинсона // Журн. неврол. и психиат. — 2008. — Т. 108, № 6. — С. 91-97.
Мищенко Т.С. Деменция — это не нозологическая форма, а синдром // НейроNews. — 2009. — № 2/1. — С. 6-9.
Селезнева Н.Д., Гаврилова С.И., Калын Я.Б. и др. Лечение болезни Альцгеймера у пациентов с сопутствующей соматической патологией // Журн. неврол. и психиат. — 2008. — Т. 108, № 7. — С. 35-42.
Фойгт Н.А. Тривалість життя в похилому віці: еволюція, сучасність, перспективи. — К., 2002. — 298 с.
Яхно Н.Н., Преображенская И.С. Деменция с тельцами Леви // Неврол. журн. — 2003. — Т. 8, № 6. — С. 4-12.
Aarsland B., Ballard C., Rongve A. et al. Clinical trials of dementia with Lewy bodies and Parkinson’s disease dementia // Clin. Neurol. Neurosci. Rep. — 2012. — V. 12. — P. 492-501.
Anand A., Patience A.A., Sharma N. et al. The present and future of pharmacotherapy of Alzheimer’s disease: a comprehensive review // Eur. J. Pharmacol. — 2017. — V. 815. — P. 364-375.
Arias E., Ales E., Gabilan N.H. et al. Galantamine prevents apoptosis induced by beta-amyloid and thapsigargin: involvement of nicotinic acetylcholine receptors // Neuropharmacology. — 2004. — V. 46. — P. 103-114.
Arendt T., Bruckner M.K., Lange M. et al. Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer’s disease resemble embryonic development — a study of molecular forms // Neurochem. Int. — 1992. — V. 21. — P. 381-396.
Ballard C., McKeith I., Burn D. et al. The UPDRS scale as a means of identifying extrapyramidal signs in patients suffering from dementia with Lewy bodies // Acta Neurol. Scand. — 1997. — V. 96. — P. 366-371.
Bent-Ennakhil N., Coste F., Xiu L. et al. A real-world analysis of treatment patterns for cholinesterase inhibitors and memantine among newly-diagnosed Alzheimer’s disease patients // Neurol. Ther. — 2017. — V. 6. — P. 131-144.
Blanco-Silvente L., Castells X., Saez M. et al. Discontinuation, efficacy and safety of cholinesterase inhibitors for Alzheimer’s disease: a meta-analysis and meta-regression of 43 randomized clinical trials enrolling 16106 patients // Int. J. Neuropsychopharmacol. — 2017. — V. 20. — P. 519-528.
Bullock R. The clinical benefits of rivastigmine may reflects its dual inhibitory mode of action: an hypothesis // Int. J. Clin. Pract. — 2002a. — V. 56. — P. 206-214.
Bullock R., Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson’s disease: a case series // Curr. Med. Res. Opin. — 2002b. — V. 18. — P. 258-264.
Bullock R., Ritchie C.W. Cholinesterase inhibitors: long-term studies // Therapeutic strategies in dementia . — Oxford: Clin. Publ, 2007. — P. 13-22.
Burn D., Emre M., McKeith I. et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease // Mov. Disord. — 2006. — V. 21. — P. 1899-1907.
Corey-Bloom J. The ABC of Alzheimer’s disease: cognitive changes and their management in Alzheimer’s disease and related dementias // Int. Psychogeriat. — 2002. — V. 14, suppl. 1. — P. 51-75.
Davis H.S., Rockwood K. Conceptualization of mild cognitive impairment: a review // Int. J. Geriatr. Psychiat. — 2004. — V. 19. — P. 313-319.
Desmond D.W. Vascular dementia // Clin. Neurosci. Res. — 2004. — V. 3. — P. 437-448.
Doody R.S., Stevens J.C., Beck C. et al. Practice parameter: management of dementia (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology // Neurology. — 2001. — V. 56. — P. 1154-1166.
Doraiswamy M., Anand R., Hartman R. Long-term cognitive effects in Alzheimer’s disease: does early initiation of therapy offer sustained benefits? // Prog. Neuropsychopharmacol. Biol. Psychiat. — 2002. — V. 26. — P. 705-712.
Emre M., Aarsland D., Albanese A. et al. Rivastigmine for dementia associated with Parkinsonn’s disease // N. Eng. J. Med. — 2004. — V. 351. — P. 2509-2518.
Emre M., Aarsland D., Brown R. et al. Clinical diagnostic criteria for dementia associated with Parkinson’s disease // Mov. Disord. — 2007. — V. 22. — P. 1689-1707.
Farlow M.R. Cummings J.L. Effective pharmacological management of Alzheimer’s disease // Amer. J. Med. — 2007. — V. 120. — P. 388-397.
Gauthier S. Alzheimer’s disease: current and future therapeutic perspectives // Progr. Neuro-Psychopharmacol. & Biol. Psychiat. — 2001. — V. 25. — P. 73-89.
Gawel K., Labuz K., Gibuta-Bruzda E. et al. Cholinesterase inhibitors, donepezil and rivastigmine, attenuates spatial memory and cognitive flexibility impairment induced by acute ethanol in the Barnes maze task in rats // Naunyn-Scmiedeberg’s Arch. Pharmacol. — 2016. — V. 389. — P. 1059-1071.
Glynn-Servedio B.E., Ranola T.S. ACHe inhibitors and MNDA receptor antagonists in advanced Alzheimer’s disease // Consult. Pharm. — 2017. — V. 32. — P. 511-518.
Greig N.H., Lahiri D.K., Sambamurti K. Butyrylcholinesterase: an important new target in Alzheimer’s disease therapy // Int. Psychogeriat. — 2002. — V. 14, suppl. 1. — P. 77-91.
Grossberg G.T. The ABC of Alzheimer’s disease: behavioural symptoms and their treatment // Int. Psychogeriat. — 2002. — V. 14, suppl. 1. — P. 27-49.
Guillozet A.L., Smiley J.F., Mash D.C. et al. Butyrylcholinesterase in the life cycle of amyloid plaques // Ann. Neurol. — 1997. — V. 42. — P. 909-918.
Hansen R.A., Gartlehner G., Webb A.P. et al. Efficacy and safety of donepezil, galantamine and rivastigmine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis // Clin. Interv. Aging. — 2008. — V. 3. — P. 211-225.
Henderson E.J., Lord S.R., Brodie A. et al. Rivastigmine for gait stability in patients with Parkinson’s disease(ReSPonD): a randomized, double-blind, placebo-controlled, phase 2 trial // Lancet Neurol. — 2016. — V. 15. — P. 249-258.
Hock C. Biochemical aspects of dementia // Dial. Clin. Neurosci. — 2003. — V. 5. — P. 27-34.
Inestrosa N., Alvarez A., Perez C. et al. Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer’s fibrils: possible role of the peripheral site of the enzyme // Neuron. — 1996. — V. 16. — P. 881-891.
Kandiah N., Pai M.C., Senanarong V. et al. Rivastigmine: the advantages of dual acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia // Clin. Interv. Aging — 2017. — V. 12. — P. 697-707.
Kimura T., Takamatsu J. Two cases of Alzheimer’s disease showing deterioration of behavioural and psychological symptoms of dementia induced by switching from rivastigmine to donepezil // Neuropsychiat. Dis. Treat. — 2013. — V. 9. — P. 49-53.
Kobayashi H., Ohnishi T., Naragawa R. et al. The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer’s disease: a Bayesian network meta-analysis // Int. J. Geriatr. Psychiat. — 2016. — V. 31. — P. 892-904.
Koller D., Hua T., Bynum J.P.W. Treatment patterns with anti-dementia drugs in the United States: Medicare cohort study // J. Amer. Geriatr. Soc. — 2016. — V. 64. — P. 1540-1548.
Kumar V., Anand R., Messina J. et al. An efficacy and safety analysis of Exelon in Akzheimer’s disease with concurrent vascular risk factors // Eur. J. Neurol. — 2000. — V. 7. — P. 159-169.
Lajkowska W., Roglewicz D., Jedrzejczak F. et al. The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer’s disease and vascular dementia // J. Neurol. Sci. — 2005. — V. 216. — P. 119-126.
Lane R.M., Potkin S.G., Enz A. Targeting acetylcholinesterase and butyrylcholinesterase in dementia // Int. J. Neuropsychopharmacol. — 2006. — V. 9. — P. 101-124.
Lang L., Clifford A., Wei L. et al. Prevalence and determinants of undetected dementia in the community: a systematic literature review and a meta-analysis // BMJ Open. — 2017. — V. 7. — e011146.
Maidment I., Fox C., Boustani M. Cholinesterase inhibitors for Parkinson’s disease dementia // Cochrane Database Syst. ReV. — 2006. — Issue 1. — Art No: CD004747.
Mamikonyan E., Sharon X.X., Melvin E. et al. Rivastigmine for mild cognitive impairment in Parkinson’s disease: a placebo-controlled study // Mov. Disord. — 2015. — V. 30. — P. 912-918.
McKeith I., Del Sec T., Spano P.F. et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomized, double-blind, placebo-controlled international study // Lancet. — 2000. — V. 356. — P. 2031-2036.
Mendez M.F., Cummings J.L. Dementia. — Philadelphia: Butterworth Heinemann, 2003. — 654 p.
Moretti R., Torre R., Antonello R.M. et al. Rivastigmine in subcortical vascular dementia: a comparison trial of efficacy and tolerability for 12 month follow-up // Eur. J. Neurol. — 2001. — V. 8. — P. 361-362.
Nordberg A., Almkvist O., Nilsson A. et al. Improved cortical glucose metabolism in AD patients treated with rivastigmine for one year // J. Neurol. Sci. — 2001. — V. 187, suppl. 1. — Abstr. P0409.
Park K.W., Kim E.-J., Han H.J. et al. Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer’s dementia associated with minimal and moderate ischemic white matter hyperintensities: a multicenter prospective open-label clinical trail // PLoS One. — 2017. — V. 12. — e0182123.
Potkin S.G., Anand R., Hartman R. et al. Impact of Alzheimer’s disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease // Progr. Neuropsychopharmacol. Biol. Psychiat. — 2002. — V. 26. — P. 713-720.
Riuz-Perez S., Tormos A.M., Perez S. et al. Vascular pathology: cause or effect in Alzheimer disease? // Neurologia. — 2018. — V. 33. — P. 112-120.
Sambamurti K., Greig N.H., Lahiri D.K. Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer’s disease // Neuro-Molec. Med. — 2002. — V. 1. — P. 1-20.
Schneider L.S., Anand R., Farlow M.R. Systematic review of the efficacy of rivastigmine for patients with Alzheimer’s disease // Int. J. Geriat. Psychopharmacol. — 1998. — V. 10. — P. 26-34.
Seppi K., Weintraub D., Coelho K. et al. The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease // Mov. Disord. — 2011. — V. 26. — P. S42-S80.
Shanks M., Kivipelto M., Bullock R. et al. Cholinesterase inhibition: is their evidence for disease-modifying effects ? // Curr. Med. Res. Opin. — 2009. — V. 25. — P. 2439-2446.
Small G.W., Kaufer D., Mendiondj A. et al. Cognitive performance in Alzheimer’s patients receiving rivastigmine for up to 5 years // Int. J. Clin. Pract. — 2005. — V. 59. — P. 473-477.
Svenningsson P., Westman E., Ballard C. et al. Cognitive impairment in patients with Parkinson’s disease: diagnosis, biomarkers, and treatment // Lancet Neurol. — 2012. — V. 11. — P. 697-707.
Weintraub D., Somogy M., Meng X. Rivastigmine in Alzheimer’s disease and Parkinson’s disease dementia: an ADAS-cog factor analysis // Amer. J. Alz. Dis. Other Demen. — 2011. — V. 26. — P. 443-449.
Wesnes K.A., McKeith I., Edgar C. et al. Benefits of rivastigmine on attention in dementia associated with Parkinson’s disease // Neurology. — 2005. — V. 65. — P. 1654-1656.
Copyright (c) 2018 INTERNATIONAL NEUROLOGICAL JOURNAL

This work is licensed under a Creative Commons Attribution 4.0 International License.
© Publishing House Zaslavsky, 1997-2020
